Hypersensitivity Pneumonitis

What hypersensitivity pneumonitis is

Hypersensitivity pneumonitis, or HP, is an immune-mediated lung disease. It develops when a susceptible person repeatedly inhales an organic antigen, small enough to reach deep into the lungs, and the immune system responds to it as a threat rather than tolerating it. That abnormal response produces inflammation in the lung tissue itself, not just the airways, and with enough repeated exposure it can eventually lead to scarring in some people.

Exposure alone does not equal disease: many people are exposed to the same birds, mold, or dusts as someone who develops HP and never develop the condition themselves, since individual immune susceptibility matters as much as the exposure itself. This is part of why the diagnostic process below has to establish both that an immune reaction is present and, where possible, what is driving it.

Common exposure sources

The exposure categories above are well recognized as genuine triggers of HP, though the list is illustrative rather than exhaustive. Identifying a relevant exposure, when one exists, is a genuinely important part of both diagnosis and management, since avoidance is a cornerstone of treatment.

Even so, a specific, identifiable antigen is not found in every person diagnosed with HP, even after a careful exposure history. This does not invalidate the diagnosis, though it can make exposure avoidance harder to design.

Symptoms

Symptoms of HP, summarized above, vary depending on the pattern of disease a person has. Some people notice symptoms that worsen in connection with specific exposures, a pattern that can be a useful clue during the history-taking process, while others, particularly those with a more established, fibrotic pattern of disease, develop a gradual, progressive breathlessness that is less obviously tied to any single exposure event.

Because these symptoms overlap substantially with other forms of interstitial lung disease and with other respiratory and cardiac conditions, symptoms by themselves cannot establish the diagnosis.

The current classification: fibrotic vs. nonfibrotic

For years, HP was often described using terms like acute, subacute, and chronic, based loosely on how quickly symptoms appeared after exposure, and some patients may still hear these older terms in conversation. Current clinical practice instead organizes HP primarily around whether fibrosis, or lung scarring, is present.

Nonfibrotic vs. Fibrotic HP

Nonfibrotic vs. Fibrotic HP

Dimension	Nonfibrotic HP	Fibrotic HP
Underlying Process	Inflammation without significant scarring visible on imaging	Established scarring on imaging, in addition to any ongoing inflammation
Response to Exposure Avoidance	Often improves substantially once the triggering exposure is addressed	Does not necessarily reverse with exposure avoidance alone
Typical Course	Generally, though not always, more responsive to treatment	Can, in some patients, follow a progressive course similar in spirit to other progressive fibrotic lung diseases such as idiopathic pulmonary fibrosis, though the two conditions have different underlying causes
Older Terminology Sometimes Heard	Roughly corresponds to what used to be called acute or subacute HP	Roughly corresponds to what used to be called chronic HP
What Actually Determines the Category	Whether fibrosis is present on imaging, not how quickly symptoms appeared	Whether fibrosis is present on imaging, not how quickly symptoms appeared

This distinction genuinely matters: symptom timing after exposure is a less reliable predictor of prognosis and treatment response than whether fibrosis is actually present on imaging. Two people with a similar pace of symptom onset can have very different outlooks once fibrosis is assessed directly, which is why fibrotic status, rather than timing, is now the primary organizing framework for HP.

How hypersensitivity pneumonitis is diagnosed

No single test reliably diagnoses HP on its own. Diagnosis is a process that weighs several types of information together.

The Diagnostic Pathway

1. 01→Detailed Exposure HistoryA thorough history covering the home environment, hobbies, occupation, and any pattern connecting symptoms to specific locations or activities is foundational, though it does not always uncover a relevant exposure. An unidentified exposure does not rule out HP.↓
2. 02High-Resolution CT (HRCT)Central to evaluating HP, revealing patterns of inflammation and, in more established disease, scarring that help determine whether disease is fibrotic or nonfibrotic. Overlap with other interstitial lung diseases means imaging alone usually is not conclusive.↓
3. 03→Serum Antibody TestingBlood testing for antibodies against specific antigens, sometimes called precipitins, is often obtained when a specific exposure is suspected. A positive result confirms exposure but not necessarily active disease, and a negative result does not rule out HP, since standard panels only test a limited set of known antigens.↓
4. 04Bronchoscopy and Bronchoalveolar LavageFrequently used when the diagnosis remains uncertain after history, imaging, and pulmonary function testing. Fluid collected during bronchoscopy can be analyzed for an elevated proportion of lymphocytes that supports an HP diagnosis, and a small tissue sample is sometimes obtained when more detail is needed.

Pulmonary function testing in HP often shows a restrictive pattern, reflecting reduced lung volumes from inflamed or scarred lung tissue, though some patients show a mixed or obstructive component. DLCO is frequently reduced as well, particularly once fibrosis is present, and serial testing over time is useful for tracking whether disease is stable or changing.

Because several forms of interstitial lung disease, including connective-tissue-disease-associated ILD, can resemble HP on any individual test, a coordinated discussion among pulmonology, radiology, and, when tissue is available, pathology is typically how a confident diagnosis is reached, the same approach used for IPF and other complex forms of interstitial lung disease.

Why the fibrotic vs. nonfibrotic distinction guides management

Management of HP is built around this classification because it meaningfully changes what treatment is likely to help and what course the disease is likely to follow, summarized in Treatment Options below.

Exposure avoidance. Whenever a specific trigger has been identified, reducing or eliminating ongoing exposure, whether that means removing pet birds from the home, addressing mold or water damage in a building, or changing an occupational exposure, can lead to meaningful improvement in nonfibrotic disease. Its effect on established fibrosis is generally more limited, since scarring that has already formed does not typically reverse.

Anti-inflammatory treatment. For active inflammation, particularly in nonfibrotic disease or the inflammatory component of fibrotic disease, anti-inflammatory therapy is a standard part of management, aimed at calming the underlying immune reaction driving lung injury.

Approaches for progressive fibrotic disease. In fibrotic HP that continues to progress despite exposure avoidance and anti-inflammatory treatment, physicians may consider approaches aimed at slowing further scarring. This reflects the broader concept of progressive pulmonary fibrosis: certain fibrotic lung diseases, HP included, can worsen over time in ways that resemble other progressive fibrotic conditions, though the underlying causes differ.

Because fibrotic and nonfibrotic HP can call for genuinely different management strategies, getting this classification right at diagnosis, and reassessing it when the clinical picture changes, is central to appropriate care.

Ongoing monitoring

HP, particularly the fibrotic pattern, generally requires ongoing follow-up rather than a single evaluation and treatment plan. Monitoring typically includes periodic pulmonary function testing to track lung volumes and gas exchange, symptom review, imaging when there is a specific concern for change, and periodic exercise-based assessment for oxygen desaturation with activity.

Because nonfibrotic and fibrotic HP can behave very differently, and because a subset of fibrotic HP can follow a progressive course, the pace and intensity of monitoring, including whether pulmonary rehabilitation may help, is tailored to the individual.

Getting an accurate diagnosis

Because HP sits at the intersection of exposure history, immune response, and lung tissue changes, and because management differs by fibrotic status, a thorough evaluation is the appropriate path to an accurate diagnosis rather than any single test result.

HP is best understood as one specific, exposure-related subtype within the much broader category of interstitial lung disease, evaluated with many of the same tools used across that category, but with its own distinct exposure-related and immune-mediated features.

For patients in the North Dallas-Fort Worth area, the pulmonary team at VitalAir Sleep & Lung Center in Frisco, Texas offers pulmonary function testing and evaluation for unexplained shortness of breath or persistent cough, which can be an appropriate starting point when hypersensitivity pneumonitis or another form of interstitial lung disease is a consideration.